Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.

@article{Vitolo2013RituximabMC,
  title={Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.},
  author={Umberto Vitolo and Marco Ladetto and Carola Boccomini and Luca Baldini and Federico De Angelis and Alessandra Tucci and Barbara Botto and Annalisa Chiappella and Annalisa Chiarenza and Antonello Pinto and Amalia De Renzo and Francesco Zaja and Claudia Castellino and Alessia Bari and Isabel Alvarez De Celis and Andrea Evangelista and Guido Parvis and Enrica Gamba and Chiara Lobetti-Bodoni and Giovannino Ciccone and Giuseppe Rossi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 27},
  pages={3351-9}
}
PURPOSE To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by rituximab consolidation. PATIENTS AND METHODS A total of 234 treatment-naive 60- to 75-year-old patients began chemoimmunotherapy with four monthly courses of rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) followed by four weekly cycles of rituximab consolidation. Of these, 210 patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…